OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Shusterman on a DNA Methylome Enrichment Platform for Early Detection of Solid Tumors

April 26th 2023

Michael Shusterman, MD, discusses findings from a retrospective study to determine the feasibility of a novel genome-wide methylome enrichment platform for the early detection of multiple solid tumors.

Nerlakanti on the Role of HDAC Inhibitors in Osteosarcoma

April 26th 2023

Niveditha Nerlakanti, discusses the investigation of HDAC inhibitors in osteosarcoma.

Dr Tauro on the Role of ULK3 in Multiple Myeloma

April 26th 2023

Marilena Tauro, PhD, discusses the role for ULK3 in regulating autophagy in multiple myeloma.

Dr Stewart on the Multiomic Landscape of Squamous Cell Lung Cancer

April 26th 2023

Paul Stewart, PhD, discusses the multiomic landscape of squamous cell lung cancer.

Dr Wu on the Role of METTL3-Mediated m6A Modification in CLL Progression

April 26th 2023

Yiming Wu, PhD, discusses a study identifying METTL3-mediated N6-methyladenosine modification as a key translational regulator of splicing factors, and how this mechanism contributes to the progression of chronic lymphocytic leukemia.

Nasr on the Need for Preclinical Models of Prostate Cancer Dormancy

April 26th 2023

Mostafa Nasr, PhD candidate, discusses the development of novel preclinical models of prostate cancer dormancy, and the significance of these outcomes may have on future research in metastatic prostate cancer.

Dr Hathaway on the Investigation of Distress on the TME in Ovarian Cancer

April 25th 2023

Cassandra A. Hathaway, MD, discusses the rationale for investigating the association between distress, such as depression, and the tumor immune microenvironment in patients with ovarian cancer.

Dr Bindra on the Role of MGMT Loss on Resistance Mechanisms in Cancer

April 25th 2023

Ranjit S. Bindra, MD, PhD, discusses a new class of DNA modifiers which selectively target tumor DNA with the goal of overcoming resistance mechanisms across multiple types of cancer.

Dr Simeone on the EVEREST-1 Trial Evaluating A2B530 in Solid Tumors

April 25th 2023

Diane M. Simeone, MD, discusses the phase 1/2 EVEREST-1 trial evaluating the autologous CAR T-cell therapy A2B530 in patients with solid tumors.

Dr. McGuinness on Mitigating GI Toxicities With PI3K Inhibitors in PI3K-Mutated Breast Cancer

April 25th 2023

Julia E. McGuinness, MD, discusses combating gastrointestinal toxicities in PI3K-mutated breast cancer.

Dr Alfonso Piérola on Unmet Needs in Higher-Risk MDS

April 25th 2023

Ana Alfonso Piérola, MD, PhD, discusses unmet needs for patients with high-risk myelodysplastic syndrome.

Dr Llanos on Prediagnositic Allostatic Load and Breast Cancer Clinicopathology in Black Women

April 25th 2023

Adana A.M. Llanos, PhD, MPH, discusses the relationship between prediagnostic allostatic load and breast cancer clinicopathology in Black women.

Dr Venugopal on Challenges With the Diagnosis of BPDCN

April 25th 2023

Sangeetha Venugopal, MD, MS, discusses the importance of increasing awareness of blastic plasmacytoid dendritic cell neoplasm to improve early diagnosis and treatment for patients with BPDCN at academic centers.

Dr Nakshatri on the Investigation of TONSL in Breast Cancers

April 25th 2023

Harikrishna Nakshatri, BVSc, PhD, discusses the investigation of TONSL in patients with breast cancer.

Dr Herbst on the Implications of the AEGEAN Trial in NSCLC

April 24th 2023

Roy S. Herbst, MD, PhD, discusses the implications of the phase 3 AEGEAN trial in patients with resectable non–small cell lung cancer.

Dr Garon on Challenges Associated With Immunotherapy Use in EGFR-mutated NSCLC

April 24th 2023

Edward B. Garon, MD, MS, discusses challenges associated with the incorporation of immunotherapy into the treatment paradigm for EGFR-mutant non–small cell lung cancer.

Dr Sullivan on Pseudoprogression as a Potential Explanation for Outcomes With Tebentafusp in Uveal Melanoma

April 24th 2023

Ryan J. Sullivan, MD, explains the prolongation of survival with tebentafusp-tebn despite apparent initial radiographic tumor progression in patients with uveal melanoma.

Dr Sullivan on ctDNA Reduction After Tebentafusp Treatment in Uveal Melanoma

April 24th 2023

Ryan J. Sullivan, MD, discusses findings from a study investigating the effects of early circulating tumor DNA reduction on overall survival in patients with uveal melanoma treated with tebentafusp.

Dr Marconi on the Investigation of Tamibarotene Plus Azacitidine in Higher-risk MDS

April 21st 2023

Giovanni Marconi, MD, discusses ongoing research with the combination of tamibarotene and azacitidine in patients with higher-risk myelodysplastic syndrome.

Dr Hamilton on the Potential of RLY-2608 in PI3K-Mutated Breast Cancer

April 21st 2023

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research, Sarah Cannon Research Institute, discusses the potential of the PI3K inhibitor RLY-2608 in PI3K-mutated breast cancer.